How Strategic Site Partnerships Can De-Risk Development Pipelines

Each day a Phase 2 or 3 trial runs late can cost up to $40,000 in direct research expenses and as much as $800,000 in lost drug sales. Even so, many sponsors and CROs still choose and launch research sites one study at a time. With every new protocol, they repeat the same checks on whether a site can enroll enough patients and negotiate a new contract. This playbook explains why that approach is now too slow and too risky, and how long-term partnerships with a network of research sites can make trials more predictable from the start.

Drawing on insights from clinical operations and recruitment leaders, the playbook shows how managing sites as one connected system changes the work. A single contract can cover many locations, and enrollment estimates can rest on real patient health records rather than optimistic guesses. Recruitment can build on trusted local relationships, and quality standards can be applied the same way everywhere. It also covers what to ask when choosing a site-network partner.